SCHEDULE: State Street Reports Stake in ADMA Biologics

State Street Corporation and SSGA Funds Management, Inc. have updated their beneficial ownership filing for ADMA Biologics Inc., reporting a combined 7.4% stake.

Summary

• State Street Corporation and SSGA Funds Management, Inc. have filed an updated Schedule 13G, indicating their beneficial ownership of ADMA Biologics Inc. common stock.
• The filing reports a combined aggregate amount of 17,116,022 shares beneficially owned, representing 7.4% of the class.
• SSGA Funds Management, Inc. individually holds 11,593,203 shares, representing 5% of the class.
• The filing is made as of June 30, 2026, and the reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• The filing indicates continued institutional interest in ADMA Biologics Inc. through the holdings of State Street and SSGA Funds Management.
• The reporting persons certify that the shares are held in the ordinary course of business, suggesting stable, long-term investment rather than activist intent.

Negatives

• The filing does not provide any new operational, financial, or strategic information about ADMA Biologics Inc., making it purely an ownership update.
• The reported stake of 7.4% by State Street Corporation and SSGA Funds Management, Inc. is a significant holding, but the filing itself offers no insight into their investment thesis or future intentions.

Risks

• While not explicitly stated as a risk in this filing, significant institutional holdings can sometimes lead to increased volatility if those institutions decide to alter their positions.
• The filing does not contain forward-looking statements, so there is no information regarding potential future risks or challenges for ADMA Biologics Inc. from this document.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or company guidance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like State Street and SSGA Funds Management, indicating their role as passive investors managing assets. The filing itself does not provide insights into ADMA Biologics' specific industry performance but rather reflects the investment landscape for biotechnology companies.

Stakeholder Impact

• Shareholders: The filing confirms significant institutional ownership, which can influence market perception and liquidity, but provides no direct operational impact.
• Management: The filing does not directly impact management unless it signals a shift in investor sentiment or potential future engagement from the reporting entities.
• Creditors: No direct impact on creditors is indicated by this ownership filing.

Next Steps

• No specific next steps are outlined in this filing beyond the ongoing reporting obligations for beneficial ownership.

Key Dates

Keywords

ADMA Biologics, State Street Corporation, SSGA Funds Management, Schedule 13G, Beneficial Ownership, Institutional Holding, Common Stock